BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 19424794)

  • 1. Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.
    MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
    Breast Cancer Res Treat; 2010 Jan; 119(2):463-74. PubMed ID: 19424794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.
    MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
    Breast Cancer Res Treat; 2010 Apr; 120(3):727-36. PubMed ID: 19672706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of menopausal hormone therapy-associated colorectal cancer risk by polymorphisms in sex steroid signaling, metabolism and transport related genes.
    Rudolph A; Sainz J; Hein R; Hoffmeister M; Frank B; Försti A; Brenner H; Hemminki K; Chang-Claude J
    Endocr Relat Cancer; 2011 Jun; 18(3):371-84. PubMed ID: 21490239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
    Colditz GA; Hankinson SE; Hunter DJ; Willett WC; Manson JE; Stampfer MJ; Hennekens C; Rosner B; Speizer FE
    N Engl J Med; 1995 Jun; 332(24):1589-93. PubMed ID: 7753136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk.
    Quick SK; Shields PG; Nie J; Platek ME; McCann SE; Hutson AD; Trevisan M; Vito D; Modali R; Lehman TA; Seddon M; Edge SB; Marian C; Muti P; Freudenheim JL
    Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1082-7. PubMed ID: 18483329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy.
    Hein R; Abbas S; Seibold P; Salazar R; Flesch-Janys D; Chang-Claude J
    Breast Cancer Res Treat; 2012 Jan; 131(2):653-61. PubMed ID: 21947678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women.
    Singh V; Rastogi N; Sinha A; Kumar A; Mathur N; Singh MP
    Breast Cancer Res Treat; 2007 Jan; 101(1):73-81. PubMed ID: 16807674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer risk with postmenopausal hormonal treatment.
    Collins JA; Blake JM; Crosignani PG
    Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic approach to analysing gene-gene interactions: polymorphisms at the microsomal epoxide hydrolase EPHX and glutathione S-transferase GSTM1, GSTT1, and GSTP1 loci and breast cancer risk.
    Spurdle AB; Chang JH; Byrnes GB; Chen X; Dite GS; McCredie MR; Giles GG; Southey MC; Chenevix-Trench G; Hopper JL
    Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):769-74. PubMed ID: 17416769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GSTM1, GSTT1, and GSTP1 polymorphism and lung cancer risk in relation to tobacco smoking.
    Schneider J; Bernges U; Philipp M; Woitowitz HJ
    Cancer Lett; 2004 May; 208(1):65-74. PubMed ID: 15105047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined effect of GSTM1, GSTT1, and COMT genotypes in individual breast cancer risk.
    Park SK; Yim DS; Yoon KS; Choi IM; Choi JY; Yoo KY; Noh DY; Choe KJ; Ahn SH; Hirvonen A; Kang D
    Breast Cancer Res Treat; 2004 Nov; 88(1):55-62. PubMed ID: 15538046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology.
    Rebbeck TR; Troxel AB; Walker AH; Panossian S; Gallagher S; Shatalova EG; Blanchard R; Norman S; Bunin G; DeMichele A; Berlin M; Schinnar R; Berlin JA; Strom BL
    Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):444-50. PubMed ID: 17372239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer.
    Mitrunen K; Jourenkova N; Kataja V; Eskelinen M; Kosma VM; Benhamou S; Vainio H; Uusitupa M; Hirvonen A
    Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):229-36. PubMed ID: 11303592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A population-based case-control study of the Arg399Gln polymorphism in DNA repair gene XRCC1 and risk of breast cancer.
    Shu XO; Cai Q; Gao YT; Wen W; Jin F; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1462-7. PubMed ID: 14693738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study.
    Le Marchand L; Donlon T; Kolonel LN; Henderson BE; Wilkens LR
    Cancer Epidemiol Biomarkers Prev; 2005 Aug; 14(8):1998-2003. PubMed ID: 16103451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
    van Leeuwen FE
    Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of breast cancer risk with a common functional polymorphism (Asp327Asn) in the sex hormone-binding globulin gene.
    Cui Y; Shu XO; Cai Q; Jin F; Cheng JR; Cai H; Gao YT; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1096-101. PubMed ID: 15894658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective study of XRCC1 (X-ray cross-complementing group 1) polymorphisms and breast cancer risk.
    Patel AV; Calle EE; Pavluck AL; Feigelson HS; Thun MJ; Rodriguez C
    Breast Cancer Res; 2005; 7(6):R1168-73. PubMed ID: 16457697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.
    Kerlikowske K; Miglioretti DL; Ballard-Barbash R; Weaver DL; Buist DS; Barlow WE; Cutter G; Geller BM; Yankaskas B; Taplin SH; Carney PA
    J Clin Oncol; 2003 Dec; 21(23):4314-21. PubMed ID: 14645420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.
    Tworoger SS; Missmer SA; Barbieri RL; Willett WC; Colditz GA; Hankinson SE
    J Natl Cancer Inst; 2005 Apr; 97(8):595-602. PubMed ID: 15840882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.